{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:20:45Z","timestamp":1788283245826,"version":"build-2803163510"},"reference-count":70,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["JASN"],"abstract":"<jats:sec>\n                    <jats:title>Key Points<\/jats:title>\n                    <jats:p>\n                      <jats:list list-type=\"bullet\">\n                        <jats:list-item>\n                          <jats:p>We found evidence for reduced vascular endothelial growth factor A and vascular endothelial growth factor receptor 2 activation in both human and mouse diabetic kidney disease.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>A monoclonal vascular endothelial growth factor receptor 1\u2013blocking antibody improved urine albumin-creatinine ratio and GFR in a mouse model of accelerated diabetic kidney disease.<\/jats:p>\n                        <\/jats:list-item>\n                        <jats:list-item>\n                          <jats:p>The mechanism for this benefit appears to be linked to increased endogenous vascular endothelial growth factor A and differentiates from lisinopril.<\/jats:p>\n                        <\/jats:list-item>\n                      <\/jats:list>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Diabetic kidney disease (DKD) remains the major cause of kidney failure. Vascular endothelial growth factor A (VEGFA)-neutralizing antibodies also cause kidney disease in normal people. The present studies explored whether endogenous VEGFA deficiency might contribute to DKD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Plasma soluble vascular endothelial growth factor receptor 1 (VEGFR1; aka sflt1), the VEGFR1 ligands VEGFA, and placental growth factor were measured in human DKD plasma samples from the Canagliflozin and Renal Events in Diabetes with Established Nephropathy Clinical Evaluation (CREDENCE) trial. We also tested the effects of monoclonal antibody designation for murinized anti-mouse VEGFR1 receptor (VGFB1), a murinized VEGFR1-blocking antibody in the uninephrectomy renin expressing adeno-associated virus db\/db DKD mouse including translational end points of serum creatinine and overall survival. Histology, transmission electron microscopy, and RNA sequencing of mouse kidneys treated with or without VGFB1 or lisinopril were compared.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Circulating soluble Flt1 and placental growth factor were higher in CREDENCE participants with lower eGFR, while intrarenal VEGFA mRNA decreased with lower eGFR. VEGFR1 blockade with the VGFB1 mAb improved overall sinistrin clearance, serum creatinine, albuminuria, BP, and kidney structure in uninephrectomy renin expressing adeno-associated virus db\/db mice. VGFB1 treatment benefit differentiated from lisinopril by increasing endothelial fenestrae and glycocalyx-related genes. Compared with lisinopril, VGFB1 also significantly increased glomerular endothelial genes including\n                      <jats:italic toggle=\"yes\">Emcn, Esm1, Ehd3,<\/jats:italic>\n                      and\n                      <jats:italic toggle=\"yes\">Exoc3l2.<\/jats:italic>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      An anti-VEGFR1 antibody restored VEGFA activity, endothelial health, and GFR in severe murine DKD. This effect was\n                      <jats:italic toggle=\"yes\">via<\/jats:italic>\n                      a mechanism distinct from lisinopril.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1681\/asn.0000001176","type":"journal-article","created":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T18:02:15Z","timestamp":1784570535000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":0,"title":["Vascular Endothelial Growth Factor Receptor 1\u2013Blocking Antibody Improves Endothelial Structure, Kidney Function, and GFR in Diabetic Mice"],"prefix":"10.1681","author":[{"given":"Jingjun","family":"Li","sequence":"first","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-7691-0030","authenticated-orcid":false,"given":"Romer A.","family":"Gonzalez Villalobos","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-1958-9051","authenticated-orcid":false,"given":"Thomas J.","family":"Rutkoski","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krista P.","family":"Farrington","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vaja","family":"Chipashvili","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gang","family":"Zheng","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0469-2123","authenticated-orcid":false,"given":"Tao","family":"Chen","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Shanghai, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6427-5933","authenticated-orcid":false,"given":"Krishna","family":"Yekkala","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1395-3172","authenticated-orcid":false,"given":"Monica","family":"Locatelli","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlamaria","family":"Zoja","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariela","family":"Benigni","sequence":"additional","affiliation":[{"name":"Istituto di Ricerche Farmacologiche Mario Negri IRCCS, Centro Anna Maria Astori, Bergamo, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7360-3302","authenticated-orcid":false,"given":"Brendon","family":"Lutnick","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Ho","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9456-1364","authenticated-orcid":false,"given":"Dermot","family":"Reilly","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9377-7497","authenticated-orcid":false,"given":"Xirong","family":"Zheng","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7727-0928","authenticated-orcid":false,"given":"Songmao","family":"Zheng","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6215-1440","authenticated-orcid":false,"given":"Russell","family":"Bialecki","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0062-0520","authenticated-orcid":false,"given":"Michael K.","family":"Hansen","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Spring House, Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7866-2544","authenticated-orcid":false,"given":"Haojia","family":"Wu","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6420-8703","authenticated-orcid":false,"given":"Benjamin D.","family":"Humphreys","sequence":"additional","affiliation":[{"name":"Division of Nephrology, Department of Medicine, Washington University in St. Louis, St. Louis, Missouri"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6721-5255","authenticated-orcid":false,"given":"Maria Chiara","family":"Magnone","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eugene","family":"Myshkin","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-371X","authenticated-orcid":false,"given":"Matthew D.","family":"Breyer","sequence":"additional","affiliation":[{"name":"Johnson and Johnson Innovative Medicine, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"issue":"10469","key":"B1-20260901","doi-asserted-by":"crossref","first-page":"2341","DOI":"10.1016\/S0140-6736(24)02246-3","article-title":"Burden of disease scenarios by state in the USA, 2022-50: a forecasting analysis for the global burden of disease study 2021","volume":"404","year":"2024","journal-title":"Lancet."},{"issue":"13","key":"B2-20260901","doi-asserted-by":"crossref","first-page":"1296","DOI":"10.1056\/NEJMoa041031","article-title":"Chronic kidney disease and the risks of death, cardiovascular events, and hospitalization","volume":"351","author":"Go","year":"2004","journal-title":"N Engl J Med."},{"issue":"20","key":"B3-20260901","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1056\/NEJMoa1605368","article-title":"Diabetes and cause-specific mortality in Mexico City","volume":"375","author":"Alegre-D\u00edaz","year":"2016","journal-title":"N Engl J Med."},{"issue":"1","key":"B4-20260901","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1210\/endrev\/bnaa025","article-title":"Microvascular dysfunction in diabetes mellitus and cardiometabolic disease","volume":"42","author":"Horton","year":"2021","journal-title":"Endocr Rev."},{"issue":"1","key":"B5-20260901","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.devcel.2011.11.002","article-title":"VEGF-induced vascular permeability is mediated by FAK","volume":"22","author":"Chen","year":"2012","journal-title":"Dev Cell."},{"issue":"6","key":"B6-20260901","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1038\/nm0603-669","article-title":"The biology of VEGF and its receptors","volume":"9","author":"Ferrara","year":"2003","journal-title":"Nat Med."},{"issue":"7","key":"B7-20260901","doi-asserted-by":"crossref","first-page":"a006502","DOI":"10.1101\/cshperspect.a006502","article-title":"Signal transduction by vascular endothelial growth factor receptors","volume":"2","author":"Koch","year":"2012","journal-title":"Cold Spring Harb Perspect Med."},{"issue":"6","key":"B8-20260901","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1161\/CIRCULATIONAHA.112.091603","article-title":"Elevated vascular endothelial growth factor receptor-2 abundance contributes to increased angiogenesis in vascular endothelial growth factor receptor-1\u2013deficient mice","volume":"126","author":"Ho","year":"2012","journal-title":"Circulation."},{"issue":"41","key":"B9-20260901","doi-asserted-by":"crossref","first-page":"25646","DOI":"10.1016\/S0021-9258(18)47298-5","article-title":"Placenta growth factor. Potentiation of vascular endothelial growth factor bioactivity, in vitro and in vivo, and high affinity binding to Flt-1 but not to Flk-1\/KDR","volume":"269","author":"Park","year":"1994","journal-title":"J Biol Chem."},{"issue":"3","key":"B10-20260901","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1152\/physrev.00028.2013","article-title":"Vascular endothelial growth factor-B in physiology and disease","volume":"94","author":"Bry","year":"2014","journal-title":"Physiol Rev."},{"issue":"22","key":"B11-20260901","doi-asserted-by":"crossref","first-page":"2570","DOI":"10.1161\/CIRCULATIONAHA.118.036099","article-title":"Endothelial cells regulate physiological cardiomyocyte growth via VEGFR2-Mediated paracrine signaling","volume":"139","author":"Kivel\u00e4","year":"2019","journal-title":"Circulation."},{"issue":"5","key":"B12-20260901","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1172\/JCI17189","article-title":"Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia","volume":"111","author":"Maynard","year":"2003","journal-title":"J Clin Invest."},{"issue":"3","key":"B13-20260901","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/HYPERTENSIONAHA.120.15338","article-title":"Total versus free placental growth factor levels in the pathogenesis of preeclampsia","volume":"76","author":"Lecarpentier","year":"2020","journal-title":"Hypertension."},{"issue":"1","key":"B14-20260901","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s12882-018-1194-9","article-title":"Renal-limited thrombotic microangiopathy after switching from bevacizumab to ramucirumab: a case report","volume":"20","author":"Yamada","year":"2019","journal-title":"BMC Nephrol."},{"issue":"2","key":"B15-20260901","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1053\/j.ajkd.2006.11.039","article-title":"Risks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysis","volume":"49","author":"Zhu","year":"2007","journal-title":"Am J Kidney Dis."},{"issue":"11","key":"B16-20260901","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1056\/NEJMoa0707330","article-title":"VEGF inhibition and renal thrombotic microangiopathy","volume":"358","author":"Eremina","year":"2008","journal-title":"N Engl J Med."},{"issue":"1","key":"B17-20260901","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10456-023-09883-8","article-title":"Capillary rarefaction: a missing link in renal and cardiovascular disease?","volume":"27","author":"Steegh","year":"2024","journal-title":"Angiogenesis"},{"issue":"6","key":"B18-20260901","doi-asserted-by":"crossref","first-page":"1765","DOI":"10.1681\/ASN.2006121304","article-title":"Interstitial vascular rarefaction and reduced VEGF-A expression in human diabetic nephropathy","volume":"18","author":"Lindenmeyer","year":"2007","journal-title":"J Am Soc Nephrol."},{"issue":"8","key":"B19-20260901","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1681\/ASN.2020111579","article-title":"Circulating soluble Fms-like tyrosine kinase in renal diseases other than preeclampsia","volume":"32","author":"Wewers","year":"2021","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B20-20260901","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1053\/j.ajkd.2019.06.009","article-title":"Change in albuminuria and GFR as end points for clinical trials in early stages of CKD: a scientific workshop sponsored by the National Kidney Foundation in Collaboration with the US food and Drug administration and European medicines agency","volume":"75","author":"Levey","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"2","key":"B21-20260901","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1056\/NEJMoa2403347","article-title":"Effects of semaglutide on chronic kidney disease in patients with type 2 diabetes","volume":"391","author":"Perkovic","year":"2024","journal-title":"N Engl J Med."},{"issue":"24","key":"B22-20260901","doi-asserted-by":"crossref","first-page":"2295","DOI":"10.1056\/NEJMoa1811744","article-title":"Canagliflozin and renal outcomes in type 2 diabetes and nephropathy","volume":"380","author":"Perkovic","year":"2019","journal-title":"N Engl J Med."},{"issue":"12","key":"B23-20260901","doi-asserted-by":"crossref","first-page":"2503","DOI":"10.1681\/ASN.2009070721","article-title":"Mouse models of diabetic nephropathy","volume":"20","author":"Brosius","year":"2009","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B24-20260901","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1681\/ASN.2017040385","article-title":"Progressive renal disease established by renin-coding adeno-associated virus-driven hypertension in diverse diabetic models","volume":"29","author":"Harlan","year":"2018","journal-title":"J Am Soc Nephrol."},{"issue":"2","key":"B25-20260901","doi-asserted-by":"crossref","first-page":"F149","DOI":"10.1152\/ajprenal.00154.2021","article-title":"Therapeutic effects of lisinopril and empagliflozin in a mouse model of hypertension-accelerated diabetic kidney disease","volume":"321","author":"\u00d8stergaard","year":"2021","journal-title":"Am J Physiolo Renal Physiol."},{"key":"B26-20260901","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.ahj.2024.02.016","article-title":"Vascular endothelial growth factors and risk of cardio-renal events: results from the CREDENCE trial","volume":"271","author":"Januzzi","year":"2024","journal-title":"Am Heart J."},{"issue":"2","key":"B27-20260901","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1038\/nm731","article-title":"Revascularization of ischemic tissues by PlGF treatment, and inhibition of tumor angiogenesis, arthritis and atherosclerosis by anti-Flt1","volume":"8","author":"Luttun","year":"2002","journal-title":"Nat Med"},{"issue":"4","key":"B28-20260901","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1258\/002367787781363381","article-title":"The association between spontaneous pyelonephritis and maturity-onset diabetes mellitus in male MM mice","volume":"21","author":"Taylor","year":"1987","journal-title":"Lab Anim."},{"issue":"7","key":"B29-20260901","doi-asserted-by":"crossref","first-page":"e3000410","DOI":"10.1371\/journal.pbio.3000410","article-title":"The ARRIVE guidelines 2.0: updated guidelines for reporting animal research","volume":"18","author":"Percie du Sert","year":"2020","journal-title":"PLoS Biol."},{"issue":"6","key":"B30-20260901","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1177\/0300985813485099","article-title":"Principles for valid histopathologic scoring in research","volume":"50","author":"Gibson-Corley","year":"2013","journal-title":"Vet Pathol."},{"issue":"3","key":"B31-20260901","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1177\/0192623318761348","article-title":"Use of severity grades to characterize histopathologic changes","volume":"46","author":"Schafer","year":"2018","journal-title":"Toxicologic Pathol."},{"issue":"3","key":"B32-20260901","doi-asserted-by":"crossref","first-page":"e90","DOI":"10.1002\/cpz1.90","article-title":"Gene set knowledge discovery with enrichr","volume":"1","author":"Xie","year":"2021","journal-title":"Curr Protoc."},{"issue":"7","key":"B33-20260901","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1016\/j.cmet.2022.05.010","article-title":"Mapping the single-cell transcriptomic response of murine diabetic kidney disease to therapies","volume":"34","author":"Wu","year":"2022","journal-title":"Cell Metab."},{"issue":"10","key":"B34-20260901","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/nmeth.4407","article-title":"Massively parallel single-nucleus RNA-seq with DroNc-seq","volume":"14","author":"Habib","year":"2017","journal-title":"Nat Methods."},{"issue":"6","key":"B35-20260901","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1681\/ASN.2021030294","article-title":"Reduced glomerular filtration in diabetes is attributable to loss of density and increased resistance of glomerular endothelial cell fenestrations","volume":"33","author":"Finch","year":"2022","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B36-20260901","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1053\/j.ajkd.2019.07.019","article-title":"Change in albuminuria and estimated GFR as end points for clinical trials in early stages of CKD: a perspective from European regulators","volume":"75","author":"Holtkamp","year":"2020","journal-title":"Am J Kidney Dis."},{"issue":"1","key":"B37-20260901","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1053\/j.ajkd.2019.08.007","article-title":"Change in estimated GFR and albuminuria as end points in clinical trials: a viewpoint from the FDA","volume":"75","author":"Thompson","year":"2020","journal-title":"Am J Kidney Dis."},{"key":"B38-20260901","doi-asserted-by":"crossref","first-page":"42845","DOI":"10.1038\/srep42845","article-title":"The CUL3-SPOP-DAXX axis is a novel regulator of VEGFR2 expression in vascular endothelial cells","volume":"7","author":"Sakaue","year":"2017","journal-title":"Sci Rep."},{"issue":"6","key":"B39-20260901","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1161\/ATVBAHA.123.318987","article-title":"BCL6B contributes to ocular vascular diseases via notch signal silencing","volume":"43","author":"Tanaka","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"5904","key":"B40-20260901","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1126\/science.1165218","article-title":"Del-1, an endogenous leukocyte-endothelial adhesion inhibitor, limits inflammatory cell recruitment","volume":"322","author":"Choi","year":"2008","journal-title":"Science."},{"issue":"7129","key":"B41-20260901","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/nature05571","article-title":"Dll4 signalling through Notch1 regulates formation of tip cells during angiogenesis","volume":"445","author":"Hellstrom","year":"2007","journal-title":"Nature."},{"issue":"17","key":"B42-20260901","doi-asserted-by":"crossref","first-page":"6119","DOI":"10.3390\/ijms21176119","article-title":"The role of endocan in selected kidney diseases","volume":"21","author":"Nalewajska","year":"2020","journal-title":"Int J Mol Sci."},{"issue":"7970","key":"B43-20260901","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1038\/s41586-023-05769-3","article-title":"An atlas of healthy and injured cell states and niches in the human kidney","volume":"619","author":"Lake","year":"2023","journal-title":"Nature."},{"issue":"3","key":"B44-20260901","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1002\/path.1711660308","article-title":"Human coronary microvessels in diabetes and ischaemia. Morphometric study of autopsy material","volume":"166","author":"Yarom","year":"1992","journal-title":"J Pathol."},{"issue":"9","key":"B45-20260901","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.2337\/dc18-2515","article-title":"Microvascular disease in patients with diabetes with heart failure and reduced ejection versus preserved ejection fraction","volume":"42","author":"Tromp","year":"2019","journal-title":"Diabetes Care."},{"issue":"5","key":"B46-20260901","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1681\/ASN.2014010060","article-title":"Tubulovascular cross-talk by vascular endothelial growth factor a maintains peritubular microvasculature in kidney","volume":"26","author":"Dimke","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"5","key":"B47-20260901","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1093\/annonc\/mdm550","article-title":"Blood pressure rise following angiogenesis inhibition by bevacizumab. A crucial role for microcirculation","volume":"19","author":"Mourad","year":"2008","journal-title":"Ann Oncol."},{"issue":"15","key":"B48-20260901","doi-asserted-by":"crossref","first-page":"12605","DOI":"10.1074\/jbc.C300012200","article-title":"Neutralization of circulating vascular endothelial growth factor (VEGF) by anti-VEGF antibodies and soluble VEGF receptor 1 (sFlt-1) induces proteinuria","volume":"278","author":"Sugimoto","year":"2003","journal-title":"J Biol Chem."},{"issue":"10","key":"B49-20260901","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1681\/ASN.2009010061","article-title":"The soluble VEGF receptor sFlt1 contributes to endothelial dysfunction in CKD","volume":"20","author":"Di Marco","year":"2009","journal-title":"J Am Soc Nephrol."},{"issue":"3","key":"B50-20260901","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1681\/ASN.2014010028","article-title":"Functional genomic annotation of genetic risk loci highlights inflammation and epithelial biology networks in CKD","volume":"26","author":"Ledo","year":"2015","journal-title":"J Am Soc Nephrol."},{"issue":"4","key":"B51-20260901","doi-asserted-by":"crossref","first-page":"e0284131","DOI":"10.1371\/journal.pone.0284131","article-title":"VEGF-A165 is the predominant VEGF-A isoform in platelets, while VEGF-A121 is abundant in serum and plasma from healthy individuals","volume":"18","author":"Yamakuchi","year":"2023","journal-title":"PLoS One."},{"key":"B52-20260901","doi-asserted-by":"crossref","first-page":"7510315","DOI":"10.1155\/2019\/7510315","article-title":"Short communication: Interaction of nerve growth factor (NGF) and vascular endothelial growth factor (VEGF) in healthy individuals","volume":"2019","author":"Groh","year":"2019","journal-title":"Dis Markers."},{"issue":"4","key":"B53-20260901","doi-asserted-by":"crossref","first-page":"429","DOI":"10.2215\/CJN.0000000000000389","article-title":"Associations of angiopoietin 2 and vascular endothelial growth factor-A concentrations with clinical end points","volume":"19","author":"Mohebi","year":"2024","journal-title":"Clin J Am Soc Nephrol."},{"issue":"11","key":"B54-20260901","doi-asserted-by":"crossref","first-page":"2559","DOI":"10.1681\/ASN.2013080906","article-title":"Integrative biology identifies shared transcriptional networks in CKD","volume":"25","author":"Martini","year":"2014","journal-title":"J Am Soc Nephrol."},{"issue":"9","key":"B55-20260901","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.2337\/db10-1181","article-title":"Transcriptome analysis of human diabetic kidney disease","volume":"60","author":"Woroniecka","year":"2011","journal-title":"Diabetes."},{"issue":"9","key":"B56-20260901","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/ki.2012.234","article-title":"Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy","volume":"82","author":"Weil","year":"2012","journal-title":"Kidney Int."},{"issue":"3","key":"B57-20260901","doi-asserted-by":"crossref","first-page":"e17838","DOI":"10.1371\/journal.pone.0017838","article-title":"Renal thrombotic microangiopathy in mice with combined deletion of endocytic recycling regulators EHD3 and EHD4","volume":"6","author":"George","year":"2011","journal-title":"PLoS One."},{"issue":"27","key":"B58-20260901","doi-asserted-by":"crossref","first-page":"24189","DOI":"10.1074\/jbc.M110.212209","article-title":"Exocyst complex component 3-like 2 (EXOC3L2) associates with the exocyst complex and mediates directional migration of endothelial cells","volume":"286","author":"Barkefors","year":"2011","journal-title":"J Biol Chem."},{"issue":"8","key":"B59-20260901","doi-asserted-by":"crossref","first-page":"3521","DOI":"10.1073\/pnas.92.8.3521","article-title":"Regulation of blood pressure by the type 1A angiotensin II receptor gene","volume":"92","author":"Ito","year":"1995","journal-title":"Proc Natl Acad Sci U S A."},{"issue":"6","key":"B60-20260901","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1097\/00005344-199606000-00011","article-title":"Effects of vascular endothelial growth factor on hemodynamics and cardiac performance","volume":"27","author":"Yang","year":"1996","journal-title":"J Cardiovasc Pharmacol."},{"issue":"11","key":"B61-20260901","doi-asserted-by":"crossref","first-page":"2209","DOI":"10.1681\/ASN.V12112209","article-title":"Cellular distribution and function of soluble guanylyl cyclase in rat kidney and liver","volume":"12","author":"Theilig","year":"2001","journal-title":"J Am Soc Nephrol."},{"issue":"1","key":"B62-20260901","doi-asserted-by":"crossref","first-page":"e2453458","DOI":"10.1001\/jamanetworkopen.2024.53458","article-title":"SPRINT treatment among adults with chronic kidney disease from 2 large health care systems","volume":"8","author":"Kurella Tamura","year":"2025","journal-title":"JAMA Netw Open."},{"issue":"12","key":"B63-20260901","doi-asserted-by":"crossref","first-page":"2059","DOI":"10.34067\/KID.0001712022","article-title":"Endothelial cell-specific molecule-1 inhibits albuminuria in diabetic mice","volume":"3","author":"Zheng","year":"2022","journal-title":"Kidney360."},{"issue":"12","key":"B64-20260901","doi-asserted-by":"crossref","first-page":"e83681","DOI":"10.1371\/journal.pone.0083681","article-title":"Dynamic changes in endothelial cell adhesion molecule nepmucin\/CD300LG expression under physiological and pathological conditions","volume":"8","author":"Umemoto","year":"2013","journal-title":"PLoS One."},{"issue":"1","key":"B65-20260901","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCRESAHA.124.325218","article-title":"Loss of the endothelial glycocalyx component EMCN leads to glomerular impairment","volume":"136","author":"Hu","year":"2025","journal-title":"Circ Res."},{"issue":"7","key":"B66-20260901","doi-asserted-by":"crossref","first-page":"4235","DOI":"10.1128\/MCB.18.7.4235","article-title":"BAZF, a novel Bcl6 homolog, functions as a transcriptional repressor","volume":"18","author":"Okabe","year":"1998","journal-title":"Mol Cell Biol."},{"issue":"11","key":"B67-20260901","doi-asserted-by":"crossref","first-page":"2688","DOI":"10.1182\/blood-2011-03-345306","article-title":"BAZF, a novel component of cullin3-based E3 ligase complex, mediates VEGFR and notch cross-signaling in angiogenesis","volume":"119","author":"Ohnuki","year":"2012","journal-title":"Blood."},{"issue":"3","key":"B68-20260901","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1634\/theoncologist.2016-0265","article-title":"Randomized phase II study of ramucirumab or icrucumab in combination with capecitabine in patients with previously treated locally advanced or metastatic breast cancer","volume":"22","author":"Vahdat","year":"2017","journal-title":"Oncologist."},{"issue":"316","key":"B69-20260901","doi-asserted-by":"crossref","first-page":"316ra193","DOI":"10.1126\/scitranslmed.aac7071","article-title":"Tissue transcriptome-driven identification of epidermal growth factor as a chronic kidney disease biomarker","volume":"7","author":"Ju","year":"2015","journal-title":"Sci Transl Med."},{"issue":"4","key":"B70-20260901","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2337\/db17-0755","article-title":"Dissection of glomerular transcriptional profile in patients with diabetic nephropathy: SRGAP2a protects podocyte structure and function","volume":"67","author":"Pan","year":"2018","journal-title":"Diabetes."}],"container-title":["Journal of the American Society of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001176","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T17:02:27Z","timestamp":1788282147000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.1681\/ASN.0000001176"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":70,"URL":"https:\/\/doi.org\/10.1681\/asn.0000001176","relation":{},"ISSN":["1046-6673","1533-3450"],"issn-type":[{"value":"1046-6673","type":"print"},{"value":"1533-3450","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"assertion":[{"value":"2026-01-31","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-13","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}